Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.64 |
| ▸ | PIM3 | Q86V86 | 19/20 | 0.64 |
| ▸ | PIM2 | Q9P1W9 | 19/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14893001 | 0.90 | PIM1 (0.59) | PIM1PIM3PIM2 | |
| SCHEMBL1910869 | 0.89 | PIM1 (0.58) | PIM1PIM3PIM2 | |
| SCHEMBL14905594 | 0.88 | PIM1 (0.59) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL10278715 | 0.87 | PIM1 (0.73) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL14891344 | 0.87 | PIM1 (0.73) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL14892705 | 0.87 | PIM1 (0.73) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL10278806 | 0.87 | PIM1 (0.73) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL1910933 | 0.85 | PIM1 (0.67) | PIM1PIM3PIM2GSK3BPRKCQ | |
| SCHEMBL1911206 | 0.84 | PIM2 (0.68) | PIM1PIM3PIM2 | |
| SCHEMBL1911208 | 0.84 | PIM2 (0.68) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |